Loading market dashboard
SciSparc Ltd.
SPRCHealthcareNASDAQIL
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd.
TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum").
Toronto, Ontario – June 3, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the “ Company ” or “ NeuroThera ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has closed its previously announced acquisition (the “ Transaction ”) of an aggregate of 56,375 ordinary shares (the “ Purchased Shares ”) in the capital of CliniQuantum Ltd. (“ CliniQuantum ”), representing approximately 54.01% of the issued and outstanding ordinary shares of CliniQuantum, pursuant to a share purchase agreement dated March 9, 2026, as amended by an amending agreement dated April 30, 2026 (collectively, the “ SPA ”), among the Company, CliniQuantum and the holders of the Purchased Shares (collectively, the “ Selling Shareholders ”). The Transaction was initially announced by news release dated March 10, 2026 and updated by news release dated May 27, 2026. As consideration for the Purchased Shares, the Company issued an aggregate of 56,600,000 common shares in the capital of the Company (the “ Consideration Shares ”) from treasury to the Selling Shareholders, representing an aggregate deemed value of approximately $9,459,954.20 (the “ Purchase Price ”) based on the 20-day volume weighted average trading price of the Company's common shares (the “ Current Market Price ”) on the TSX Venture Exchange (the “ TSXV ”) as at the date of the SPA. No cash consideration was paid for the Purchased Shares.
TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction”).
TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange ("TSX") for the acquisition of approximately 54% interest in CliniQuantum Ltd.
Toronto, Ontario – May 27, 2026 - TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is providing the following update with respect to its previously announced proposed acquisition (the " Transaction ") of approximately 54.01% of the issued and outstanding ordinary shares (the “ Purchased Shares ”) of CliniQuantum Ltd. (" CliniQuantum "), as initially announced by news release dated March 10, 2026. The Company is providing this news release to supplement the disclosure contained in its March 10, 2026 news release, including in respect of (i) the license agreement between CliniQuantum and Quantum X Labs Ltd., (ii) the basis for the consideration payable under the Transaction and the fairness opinion received by the Company's board of directors, (iii) certain amendments to the share purchase agreement dated March 9, 2026 (the “ SPA ”) between the Company, CliniQuantum and the holders of the Purchased Shares (the “ Selling Shareholders ”), including the establishment of a floor price for future share issuances, an extension of the outside date, and the execution of lock-up arrangements by the Selling Shareholders as a condition of closing.
May 20, 2026 – TheNewswire - Toronto, Ontario, Canada - Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“ SciSparc ”), announces that it has adopted a semi-annual financial reporting (" SAR ") framework, effective immediately. This change is being made pursuant to the Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (" CBO 51-933 "). CBO 51-933 allows eligible venture issuers to voluntarily move from a quarterly to a semi-annual financial reporting framework.
April 30, 2026 – TheNewswire - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“ SciSparc ”), is pleased to announce that it has continued out of the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) into the provincial jurisdiction of Ontario under the Business Corporations Act (Ontario) (the " OBCA "). Shareholders approved the continuance into the OBCA by special resolution at the Company's special meeting of shareholders held on April 10, 2026. In connection with the continuance, the Company has replaced its notice of articles and articles with new articles of continuance and by-laws, respectively, under the OBCA, which can be accessed at the Company's profile at www.sedarplus.com . The CUSIP / ISIN numbers for the Company's common shares and the stock symbol for the Company's common shares remain unchanged.
April 23, 2026 – TheNewswire - Vancouver, British Columbia, Canada - Neurothera Labs Inc. (TSXV: NTLX) ( “ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), today announced that it has engaged bullVestor Median GmbH (“ bullVestor ”) pursuant to an investor relations agreement dated April 23, 2026 for assistance with its investor awareness marketing campaign. bullVestor provides marketing and investor relations services and will assist the Company in enhancing its visibility with potential investors by providing, among other services, content creation management, keyword optimization, ad groups and display ads, project management, and media distribution for a total cost of euro 300,000 for a 6-month period commencing on or about the date on which the TSX Venture Exchange (“ TSXV ”) approves the engagement (the “ TSXV Approval ”). Pursuant to the agreement respecting the engagement, euro 150,000 is payable within seven days following the date of the TSXV Approval, with the remaining euro 150,000 being payable within 45 days following the date of the TSXV Approval. bullVestor is an arm's length party from the Company and principally operates out of Austria. As of the date of this press release, to the knowledge of the Company, neither bullVestor nor any of its directors and officers own any interest, directly or indirectly, in the securities of the Company. bullVestor's engagement is subject to approval of the TSXV.
Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and SciSparc (NASDAQ: SPRC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk. Earnings and Valuation This table compares Madrigal Pharmaceuticals and
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera's ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).
Vancouver, British Columbia – TheNewswire - March 16, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announces that pursuant to its ongoing collaboration with Clearmind Medicine Inc. (“ Clearmind ”), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.
TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease).
Vancouver, British Columbia – March 11, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). The patent publication highlights the potential of a 5-methoxy-2-aminoindane (MEAI)- Palmitoylethanolamide (PEA) combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately 30% of the global adult population . Moreover, due to the presumed mechanism of action of the combination, this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD.
TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. (“CliniQ”) and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing of the transaction (the “Transaction”). CliniQ is a quantum technology company holding patents from Ramot at the Tel Aviv University, in the field of quantum simulation and quantum Monte Claro.
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). This novel therapy integrates Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), provided through its collaboration with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd.
Vancouver, British Columbia – March 10, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has entered into a definitive share purchase agreement (the " SPA ") dated March 9, 2026 between the Company, CliniQuantum Ltd. (“ CliniQ ”) and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the " CliniQ Shares "), a quantum technology company in the field of quantum simulation and quantum based Monte Claro (the " Transaction "). CliniQ is developing a next-generation platform to transform clinical trials with the power of quantum computing. Its aim is to unlock insights hidden in massive, complex datasets to design smarter, faster, and more adaptive studies. Transaction Overview
